Kerry Rogers, MD, of the Ohio State University Comprehensive Cancer Center, joins Blood Cancers Today to discuss the chronic lymphocytic leukemia (CLL) debate at the Society of Hematologic Oncology 2024 Annual Meeting. Dr. Rogers debated against Inhye Ahn, MD, of the Dana-Farber Cancer Institute, on whether therapy with Bruton tyrosine kinase inhibitors can be discontinued.